预约演示
更新于：2025-04-19
AZD-4877
更新于：2025-04-19
概要
基本信息
原研机构 |
在研机构- |
最高研发阶段终止临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H33N5O2S |
InChIKeySMFXSYMLJDHGIE-UHFFFAOYSA-N |
CAS号758722-49-5 |
关联
8
项与 AZD-4877 相关的临床试验EUCTR2008-000907-27-DE
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Urothelial Cancer
NCT00661609
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients With Recurrent Advanced Urothelial Cancer
JPRN-jRCT2080220530
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies
100 项与 AZD-4877 相关的临床结果
登录后查看更多信息
100 项与 AZD-4877 相关的转化医学
登录后查看更多信息
100 项与 AZD-4877 相关的专利（医药）
登录后查看更多信息
10
项与 AZD-4877 相关的文献（医药）2022-01-01Acta virologica
A gene expression signature that correlates with CD8+T cell expansion
in acute Epstein-Barr virus infection
Article
作者: Chen, Yijing ; Wang, Hanqing ; Liu, Xia ; Luo, Bing
Acute infectious mononucleosis (AIM) is associated with Epstein-Barr virus (EBV) infection. We explored molecular mechanisms regarding the expression of CD8+T cells in convalescence stage (CONV). Differentially expressed genes (DEGs) were identified by analyzing GEO expression profiles. Subsequently, Gene Set Enrichment Analysis (GSEA), Protein-Protein Interactions (PPI) network, and gene-micro RNAs networks were used to identify hub genes and associated pathways. GSEA provided evidence that the top 3 gene sets in GSEA were all related to integrins. We identified ten hub genes in the PPI network and DGIdb was applied to predict potential targets that might reverse the expression of hub genes. Our study enhances a mechanistic understanding of the CD8+T cells expansion in acute EBV infection and provides potential treatment targets for further research. Keywords: acute infectious mononucleosis; bioinformatics; CD8+T cells; differentially expressed genes; EBV.
2021-12-01BMC cancer2区 · 医学
Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies
2区 · 医学
ArticleOA
作者: James, G D ; Symeonides, S ; Marshall, J ; Young, J ; Clack, G
Abstract:
Background:
The continual reassessment method (CRM) identifies the maximum tolerated dose (MTD) more efficiently and identifies the true MTD more frequently compared to standard methods such as the 3 + 3 method. An initial estimate of the dose-toxicity relationship (prior skeleton) is required, and there is limited guidance on how to select this. Previously, we compared the CRM with six different skeletons to the 3 + 3 method by conducting post-hoc analysis on a phase 1 oncology study (AZD3514), each CRM model reduced the number of patients allocated to suboptimal and toxic doses. This manuscript extends this work by assessing the ability of the 3 + 3 method and the CRM with different skeletons in determining the true MTD of various “true” dose-toxicity relationships.
Methods:
One thousand studies were simulated for each “true” dose toxicity relationship considered, four were based on clinical trial data (AZD3514, AZD1208, AZD1480, AZD4877), and four were theoretical. The 3 + 3 method and 2-stage extended CRM with six skeletons were applied to identify the MTD, where the true MTD was considered as the largest dose where the probability of experiencing a dose limiting toxicity (DLT) is ≤33%.
Results:
For every true dose-toxicity relationship, the CRM selected the MTD that matched the true MTD in a higher proportion of studies compared to the 3 + 3 method. The CRM overestimated the MTD in a higher proportion of simulations compared to the 3 + 3 method.The proportion of studies where the correct MTD was selected varied considerably between skeletons. For some true dose-toxicity relationships, some skeletons identified the true MTD in a higher proportion of scenarios compared to the skeleton that matched the true dose-toxicity relationship.
Conclusion:
Through simulation, the CRM generally outperformed the 3 + 3 method for the clinical and theoretical true dose-toxicity relationships. It was observed that accurate estimates of the true skeleton do not always outperform a generic skeleton, therefore the application of wide confidence intervals may enable a generic skeleton to be used. Further work is needed to determine the optimum skeleton.
2013-08-01Investigational new drugs3区 · 医学
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer
3区 · 医学
Article
作者: Simon Chowdhury ; Arkadiusz Z. Dudek ; Tony Elliott ; Volker Muller-Mattheis ; Marc-Oliver Grimm ; Graham Mead ; John D. Chester ; Jacqueline Vuky ; Peter Albers ; Jianguo Li ; Jose Angel Arranz ; Jurgen E. Gschwend ; Anna Osmukhina ; Jeffrey Skolnik ; Gary Hudes ; Robert Jones ; Christian Wulfing
BACKGROUND:
AZD4877 is a potent inhibitor of the mitotic spindle kinesin, Eg5. Early-phase clinical studies in a broad range of cancers showed that AZD4877 is well tolerated. This Phase II study evaluated the efficacy, safety and pharmacokinetics (Cmax) of AZD4877 in patients with previously treated advanced urothelial cancer (ClinicalTrials.gov identifier NCT00661609).
PATIENTS AND METHODS:
AZD4877 25 mg was administered once-weekly for 3 weeks of each 4-week cycle until disease progression, death, unacceptable toxicity or withdrawal. The primary objective was to determine the objective response rate (RECIST). Recruitment was to be halted if ≤ 2 of the first 20 evaluable patients achieved an objective tumor response. Cmax was assessed on days 1 and 8 of cycle 1.
RESULTS:
None of the first 20 patients evaluable for efficacy achieved an objective response; enrollment was therefore halted. During this initial analysis, a further 21 patients were recruited. Overall, 39 patients were evaluable for efficacy, including one with confirmed partial response (PR) and seven patients with stable disease for ≥ 8 weeks (including one unconfirmed PR). The most commonly reported treatment-related adverse events (TRAEs) were neutropenia (22 patients), fatigue (12), leukopenia (7) and constipation (6); the most commonly reported grade ≥ 3 TRAE was neutropenia (21). Four patients had serious TRAEs. On days 1 and 8, the geometric mean Cmax of AZD4877 was 138 ng/ml (CV = 75 %) and 144 ng/ml (CV = 109 %), respectively.
CONCLUSIONS:
AZD4877 was generally tolerable in patients with advanced urothelial cancer. Given the limited clinical efficacy, further development of AZD4877 in urothelial cancer is not planned.
100 项与 AZD-4877 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膀胱癌 | 临床2期 | 美国 | 2008-05-01 | |
| 膀胱癌 | 临床2期 | 加拿大 | 2008-05-01 | |
| 膀胱癌 | 临床2期 | 德国 | 2008-05-01 | |
| 膀胱癌 | 临床2期 | 西班牙 | 2008-05-01 | |
| 膀胱癌 | 临床2期 | 英国 | 2008-05-01 | |
| 肾盂癌 | 临床2期 | 美国 | 2008-05-01 | |
| 肾盂癌 | 临床2期 | 加拿大 | 2008-05-01 | |
| 肾盂癌 | 临床2期 | 德国 | 2008-05-01 | |
| 肾盂癌 | 临床2期 | 西班牙 | 2008-05-01 | |
| 肾盂癌 | 临床2期 | 英国 | 2008-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 39 | AZD4877 25 mg | 願鑰憲簾製壓鬱襯構醖(選鏇簾顧鬱網獵窪淵選) = 6 patients 夢簾襯憲廠鬱鹹艱範壓 (壓憲簾獵膚鑰遞蓋膚膚 ) 更多 | 不佳 | 2013-08-01 | ||
临床1/2期 | 47 | 蓋製醖顧製淵願醖衊襯(淵壓鬱觸選遞窪築鏇壓) = 願築淵淵夢簾繭製鬱鹽 窪淵襯製鹹淵廠衊憲齋 (鹽醖壓鏇淵蓋鬱積鏇淵 ) | 不佳 | 2012-06-01 | |||
临床2期 | 54 | 膚簾醖齋膚憲獵壓糧壓 = 選醖憲鏇壓簾遞願蓋鑰 顧憲鑰憲襯簾繭齋選繭 (壓糧積襯窪鹽積憲製願, 簾鹽遞糧襯遞餘鹹築構 ~ 廠鹹鹽顧遞膚築鏇鑰淵) 更多 | - | 2011-01-12 | |||
临床1期 | 24 | 糧構選衊繭蓋衊鏇齋簾(積選壓衊構築鬱鑰齋齋) = Mucositis was the DLT at 18 mg/day; with 1 pt developing Gr 3 palmar-plantar syndrome at this dose 醖鹽網鏇繭鬱網築糧鹽 (醖鬱遞醖構鹽構襯選顧 ) 更多 | - | 2009-05-20 | |||
临床1期 | - | 顧廠鏇構積鑰網顧遞簾(壓網繭窪膚鏇鹽鬱蓋簾) = 夢簾鹽壓鏇齋鬱淵淵觸 簾願艱顧鏇繭憲衊繭構 (網鏇蓋艱簾積遞鑰壓膚 ) 更多 | - | 2008-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用